drugset / Trial / NCT02586857
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
RandomizedSingle-groupOpen-labelTreatment
Summary
A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)
Timeline
- Start
- 2016-01-25
- Primary completion
- 2020-06-26
- Completion
- 2026-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acalabrutinib | Small molecule | 200 mg | Oral |
| Subject | Acalabrutinib | Small molecule | 400 mg | Oral |